Qiagen NV (QIA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The companys sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify the genetic information of a pathogen in a tumor; bioinformatics solutions to analyze and interpret genomic data; and solutions to automate the use of consumables into efficient molecular testing workflows. It serves human healthcare, forensics, veterinary diagnostics, food safety testing, pharmaceutical and biotechnology and life sciences research markets. The company offers its products through subsidiaries and a network of independent distributors. It has operations in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Qiagen is headquartered in Venlo, the Netherlands.

Qiagen NV (QIA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 6
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Qiagen NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11
Qiagen NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Qiagen NV, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Numaferm Raises Additional Funds through Seed Financing 15
Protagen Raises USD12.5 Million in Venture Financing 16
Curetis Raises USD18 Million in Extended Series B Venture Financing 17
Private Equity 19
Sobera Capital And Triginta Capital Divest Stake In Biobase Through Management Buyout 19
Partnerships 20
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 20
Biobase Enters Into Licensing Agreement With University of Southern California And Childrens Hospital of Philadelphia 21
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 22
Bristol-Myers Squibb and Qiagen Enter into Agreement 23
Qiagen Enters into Agreement with Genohm 24
Qiagen Enters into Agreement with Mirati Therapeutics 25
DNAnexus Enters into Partnership with Qiagen 26
Qiagen Enters into Agreement with GATC Biotech 27
Tokai Pharma Expands Agreement with Qiagen 28
Tokai Pharma Expands Agreement with Qiagen 29
Qiagen Enters into Agreement with ArcherDx 30
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 31
AstraZeneca Enters into Co-Development Agreement with Qiagen 32
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 33
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 34
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 35
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 36
ShanghaiBio Enters Into Agreement With Ingenuity Systems 37
Atlas Biolabs Enters Into Agreement With Ingenuity Systems 38
Convey Computer Enters Into Technology Integration Agreement With CLC bio 39
QIAGEN Enters Into Joint Venture Agreement With Bio-X Center 40
Labcyte Enters Into Technology Integration Agreement With QIAGEN 41
Licensing Agreements 42
Exiqon Enters into Licensing Agreement with Aarhus University Hospital 42
Exiqon Enters into Licensing Agreement with Aarhus University Hospital 43
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 44
Sygnis Pharma Enters Into Licensing Agreement With Qiagen For Amplification Buffer 45
Inserm Transfert Enters into Licensing Agreement with HalioDx 46
Transgenomic Expands Licensing Agreement with Exiqon 47
Roche Molecular Enters into Licensing Agreement with Qiagen 48
Helicos BioSciences Enters Into Licensing Agreement With Intelligent Bio-Systems For Single Molecule Sequencing Technology Patents 49
Genetrix Enters Into Licensing Agreement With Qiagen For Qualiphi 50
Equity Offering 51
Exiqon Completes Private Placement Of Shares For US$2.6 Million 51
Debt Offering 52
Qiagen Raises USD400 Million in Private Placement of Notes 52
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 53
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 54
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 55
Exiqon Completes Private Placement Of Bonds For US$3 Million 56
Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 57
Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 58
Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 59
Acquisition 60
Qiagen Acquires OmicSoft 60
Qiagen Acquires Exiqon for up to USD102.4 Million 61
Qiagen Acquires MO BIO Labs 63
Qiagen Acquires Enzymatics 64
Qiagen Acquires Biobase 65
Qiagen Acquires Ingenuity Systems 66
CLC bio Acquires Molegro, Developer Of Drug Discovery Software 67
Qiagen Acquires Intelligent Bio-Systems 68
Qiagen NV - Key Competitors 69
Qiagen NV - Key Employees 70
Qiagen NV - Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Joint Venture 74
Recent Developments 75
Financial Announcements 75
May 02, 2018: QIAGEN Announces First Quarter 2018 Financial Results 75
Jan 31, 2018: QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase 78
Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 83
May 02, 2017: QIAGEN reports results for first quarter 2017 86
Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 88
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91

List Of Tables

List of Tables
Qiagen NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Qiagen NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Qiagen NV, Deals By Therapy Area, 2012 to YTD 2018 10
Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11
Qiagen NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Numaferm Raises Additional Funds through Seed Financing 15
Protagen Raises USD12.5 Million in Venture Financing 16
Curetis Raises USD18 Million in Extended Series B Venture Financing 17
Sobera Capital And Triginta Capital Divest Stake In Biobase Through Management Buyout 19
Qiagen Enters Into Licensing Agreement With CeMM For Calreticulin Biomarker 20
Biobase Enters Into Licensing Agreement With University of Southern California And Childrens Hospital of Philadelphia 21
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 22
Bristol-Myers Squibb and Qiagen Enter into Agreement 23
Qiagen Enters into Agreement with Genohm 24
Qiagen Enters into Agreement with Mirati Therapeutics 25
DNAnexus Enters into Partnership with Qiagen 26
Qiagen Enters into Agreement with GATC Biotech 27
Tokai Pharma Expands Agreement with Qiagen 28
Tokai Pharma Expands Agreement with Qiagen 29
Qiagen Enters into Agreement with ArcherDx 30
Protagen Enters into Agreement with Qiagen to Develop Novel Protein-Based Companion Diagnostics 31
AstraZeneca Enters into Co-Development Agreement with Qiagen 32
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 33
Qiagen Forms Joint Venture With BioBay To Establish Translational Medicine Center 34
Ingenuity Systems Enters Into Co-Promotion Agreement With Affymetrix For Research Tools 35
Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 36
ShanghaiBio Enters Into Agreement With Ingenuity Systems 37
Atlas Biolabs Enters Into Agreement With Ingenuity Systems 38
Convey Computer Enters Into Technology Integration Agreement With CLC bio 39
QIAGEN Enters Into Joint Venture Agreement With Bio-X Center 40
Labcyte Enters Into Technology Integration Agreement With QIAGEN 41
Exiqon Enters into Licensing Agreement with Aarhus University Hospital 42
Exiqon Enters into Licensing Agreement with Aarhus University Hospital 43
Qiagen Enters into Licensing Agreement with University of Tokyo for SF3B1 44
Sygnis Pharma Enters Into Licensing Agreement With Qiagen For Amplification Buffer 45
Inserm Transfert Enters into Licensing Agreement with HalioDx 46
Transgenomic Expands Licensing Agreement with Exiqon 47
Roche Molecular Enters into Licensing Agreement with Qiagen 48
Helicos BioSciences Enters Into Licensing Agreement With Intelligent Bio-Systems For Single Molecule Sequencing Technology Patents 49
Genetrix Enters Into Licensing Agreement With Qiagen For Qualiphi 50
Exiqon Completes Private Placement Of Shares For US$2.6 Million 51
Qiagen Raises USD400 Million in Private Placement of Notes 52
Exiqon Raises USD5.8 Million in Private Placement of 9.25% Note 53
Qiagen Completes Public Offering Of Senior Notes Due 2021 For US$300 Million 54
Qiagen Completes Public Offering Of Senior Notes Due 2019 For US$430 Million 55
Exiqon Completes Private Placement Of Bonds For US$3 Million 56
Qiagen Raises USD300 Million in Private Placement of 3.75% Notes Due 2022 57
Qiagen Raises USD73 Million in Private Placement of 3.19% Notes Due 2019 58
Qiagen Raises USD27 Million in Private Placement of 3.9% Notes Due 2024 59
Qiagen Acquires OmicSoft 60
Qiagen Acquires Exiqon for up to USD102.4 Million 61
Qiagen Acquires MO BIO Labs 63
Qiagen Acquires Enzymatics 64
Qiagen Acquires Biobase 65
Qiagen Acquires Ingenuity Systems 66
CLC bio Acquires Molegro, Developer Of Drug Discovery Software 67
Qiagen Acquires Intelligent Bio-Systems 68
Qiagen NV, Key Competitors 69
Qiagen NV, Key Employees 70
Qiagen NV, Subsidiaries 71
Qiagen NV, Joint Venture 74

List Of Figures

List of Figures
Qiagen NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Qiagen NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Qiagen NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Qiagen NV, Medical Devices Deals, 2012 to YTD 2018 11

Qiagen NV (QIA) - Product Pipeline Analysis, 2019 Update

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The companys sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay

USD 750 View Report

Qiagen: Performance, Capabilities, Goals and Strategies in the Global Diagnostics Market

This report is part of the Competitive Analysis Series prepared by LeadingMarketResearch.com to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation

USD 950 View Report

Qiagen NV (QIA) - Product Pipeline Analysis, 2019 Update

Qiagen NV (Qiagen) is a provider of molecular testing solutions. The companys sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay

USD 750 View Report

Qiagen NV Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Qiagen NV Company Profile is a detailed strategic and analytical report on Qiagen NV. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available